UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I Nai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties

Journal of medicinal chemistry, 2016-10, Vol.59 (19), p.9005-9017

2016

Volltextzugriff (PDF)

Drug Annotations Series Change in Guidelines

Journal of medicinal chemistry, 2019-03, Vol.62 (5), p.2217-2217

2019

Volltextzugriff (PDF)

Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)

Bioorganic & medicinal chemistry letters, 2018-02, Vol.28 (3), p.541-546

2018

Volltextzugriff (PDF)

Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor

Bioorganic & medicinal chemistry letters, 2002-10, Vol.12 (20), p.2935-2939

2002

Volltextzugriff (PDF)

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (14), p.3793-3797

2004

Volltextzugriff (PDF)

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I Na i) of the cardiac Na V 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3202-3206

2016

Volltextzugriff (PDF)

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I Na i) of the cardiac Na v 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3207-3211

2016

Volltextzugriff (PDF)

Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF)

Current topics in medicinal chemistry, 2004-04, Vol.4 (8), p.839-854

2004

Volltextzugriff (PDF)

Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics

Biophysical journal, 2010-01, Vol.98 (3), p.113a-113a

2010

Volltextzugriff (PDF)

Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)

Current topics in medicinal chemistry, 2004, Vol.4 (8), p.839

2004

Volltextzugriff (PDF)

Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A 1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

Bioorganic & medicinal chemistry letters, 2004, Vol.14 (2), p.535-539

2004

Volltextzugriff (PDF)

Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Bioorganic & medicinal chemistry letters, 2004-07, Vol.14 (14), p.3793-3797

2004

Volltextzugriff (PDF)

CVT-4325: A Potent Fatty Acid Oxidation Inhibitor with Favorable Oral Bioavailability

ChemInform, 2005-04, Vol.36 (15), p.no-no

2005

Volltextzugriff (PDF)

Structure‐Affinity Relationships of the Affinity of 2‐Pyrazolyl Adenosine Analogues for the Adenosine A 2A Receptor

ChemInform, 2003-02, Vol.34 (8)

2003

Volltextzugriff (PDF)

Structure-Affinity Relationships of the Affinity of 2-Pyrazolyl Adenosine Analogues for the Adenosine A2A Receptor

ChemInform, 2003-02, Vol.34 (8), p.no-no

2003

Volltextzugriff (PDF)

A1 adenosine receptor agonists and their potential therapeutic applications

Expert opinion on investigational drugs, 2008-12, Vol.17 (12), p.1901-1910

2008

Volltextzugriff (PDF)

A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias

The Journal of pharmacology and experimental therapeutics, 2013-01, Vol.344 (1), p.23-32

2013

Volltextzugriff (PDF)

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi

Bioorganic & medicinal chemistry letters, 2019-08, Vol.29 (16), p.2428-2436

2019

Volltextzugriff (PDF)

The Drug Annotations Series

Journal of medicinal chemistry, 2013-09, Vol.56 (17), p.6541-6541

2013

Volltextzugriff (PDF)

Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency

Bioorganic & medicinal chemistry letters, 2016-12, Vol.26 (24), p.5926-5930

2016

Volltextzugriff (PDF)

Molecule Evoluator CIDRUX BV, Park Oosterspaarn 6, 2036 MB Haarlem, The Netherlands. www. cidrux.com. See Web site for pricing information

Journal of the American Chemical Society, 2007-10, Vol.129 (41), p.12586-12586

Zablocki, Jeff

2007

Volltextzugriff (PDF)

Marked difference in saxitoxin and tetrodoxin affinity for the human nociceptive voltage-gated sodium channel (Naᵥ1.7)

Proceedings of the National Academy of Sciences - PNAS, 2012-10, Vol.109 (44), p.18102-18107

2012

Volltextzugriff (PDF)

A1 adenosine receptor antagonists, agonists, and allosteric enhancers

Handbook of experimental pharmacology, 2009 (193), p.25

2009

Volltextzugriff (PDF)

The novel late Na+ current inhibitor, GS‐6615 (eleclazine) and its anti‐arrhythmic effects in rabbit isolated heart preparations

British journal of pharmacology, 2016-11, Vol.173 (21), p.3088-3098

2016

Volltextzugriff (PDF)

How Can Rates of Prostate-Specific Antigen Screening Be Reduced in Men Aged 80 and Older?

Journal of the American Geriatrics Society (JAGS), 2010-04, Vol.58 (4), p.757-759

2010

Volltextzugriff (PDF)

1 – 25 von 63

Suche als RSS-Feed

Aktive Filter

ThemaRats

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(61)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I Nai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties

Drug Annotations Series Change in Guidelines

Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)

Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor

Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I Na i) of the cardiac Na V 1.5 channel with improved efficacy and potency relative to ranolazine

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I Na i) of the cardiac Na v 1.5 channel with improved efficacy and potency relative to ranolazine

Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF)

Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics

Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF)

Affinity and intrinsic efficacy (IE) of 5′-carbamoyl adenosine analogues for the A 1 adenosine receptor—efforts towards the discovery of a chronic ventricular rate control agent for the treatment of atrial fibrillation (AF)

Structure–affinity relationships of 5 ′ -aromatic ethers and 5 ′ -aromatic sulfides as partial A 1 adenosine agonists, potential supraventricular anti-arrhythmic agents

CVT-4325: A Potent Fatty Acid Oxidation Inhibitor with Favorable Oral Bioavailability

Structure‐Affinity Relationships of the Affinity of 2‐Pyrazolyl Adenosine Analogues for the Adenosine A 2A Receptor

Structure-Affinity Relationships of the Affinity of 2-Pyrazolyl Adenosine Analogues for the Adenosine A2A Receptor

A1 adenosine receptor agonists and their potential therapeutic applications

A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias

Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi

The Drug Annotations Series

Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potency

Molecule Evoluator CIDRUX BV, Park Oosterspaarn 6, 2036 MB Haarlem, The Netherlands. www. cidrux.com. See Web site for pricing information

Marked difference in saxitoxin and tetrodoxin affinity for the human nociceptive voltage-gated sodium channel (Naᵥ1.7)

A1 adenosine receptor antagonists, agonists, and allosteric enhancers

The novel late Na+ current inhibitor, GS‐6615 (eleclazine) and its anti‐arrhythmic effects in rabbit isolated heart preparations

How Can Rates of Prostate-Specific Antigen Screening Be Reduced in Men Aged 80 and Older?

Aktive Filter

Suchergebnisse filtern